Advertisement
Canadian Journal of Cardiology

Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference

      Abstract

      While the proportion of patients with significant statin-associated adverse effects or intolerance is very low, the increasing use and broadening indications have led to a significant absolute number of such patients commonly referred to tertiary care facilities and specialists. This report provides a comprehensive overview of the evidence pertaining to a broad variety of statin-associated adverse effects followed by a consensus approach for the prevention, assessment, diagnosis, and management. The overview is intended both to provide clarification of the untoward effects of statins and to impart confidence in managing the most common issues in a fashion that avoids excessive ancillary testing and/or subspecialty referral except when truly necessary. The ultimate goal is to ensure that patients who warrant cardiovascular risk reduction can be treated optimally, safely, and confidently with statin medications or alternatives when warranted.

      Résumé

      Bien que la proportion de patients ayant des effets indésirables importants ou une intolérance associés aux statines soit très faible, leur utilisation croissante et leurs indications diversifiées ont mené à un nombre important de patients couramment dirigés vers des établissements et des spécialistes en soins tertiaires. Ce rapport fournit un survol complet de la preuve concernant une grande variété d'effets indésirables associés aux statines suivi par une approche consensuelle de la prévention, de l'évaluation, du diagnostic et de la gestion. Ce survol est destiné à fournir à la fois une clarification des effets déplorables des statines et à donner confiance en la gestion des enjeux les plus fréquents de manière à éviter les tests auxiliaires excessifs ou les références en sous-spécialités, ou les deux, excepté lorsque cela est vraiment nécessaire. Le but ultime est de s'assurer que les patients qui bénéficieraient d'une réduction du risque cardiovasculaire peuvent être traités de manière optimale, en sûreté et en toute confiance par des statines ou d'autres solutions lorsqu'elles sont justifiées.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Baigent C.
        • Keech A.
        • Kearney P.M.
        • et al.
        Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
        Lancet. 2005; 366: 1267-1278
        • Mora S.
        • Glynn R.J.
        • Hsia J.
        • et al.
        Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity c-reactive protein or dyslipidemia.
        Circulation. 2010; 121: 1069-1077
        • Ridker P.M.
        • Danielson E.
        • Fonseca F.A.
        • et al.
        Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
        N Engl J Med. 2008; 359: 2195-2207
        • Ford E.S.
        • Ajani U.A.
        • Croft J.B.
        • et al.
        Explaining the decrease in U.S. deaths from coronary disease, 1980-2000.
        N Engl J Med. 2007; 356: 2388-2398
        • Law M.
        • Rudnicka A.R.
        Statin safety: a systematic review.
        Am J Cardiol. 2006; 97: 52C-60C
        • Joy T.R.
        • Hegele R.A.
        Narrative review: statin-related myopathy.
        Ann Intern Med. 2009; 150: 858-868
        • Thompson P.D.
        • Clarkson P.M.
        • Rosenson R.S.
        An assessment of statin safety by muscle experts.
        Am J Cardiol. 2006; 97: 69C-76C
        • Phillips P.S.
        • Haas R.H.
        • Bannykh S.
        • et al.
        Statin-associated myopathy with normal creatine kinase levels.
        Ann Intern Med. 2002; 137: 581-585
        • Giordano N.
        • Senesi M.
        • Mattii G.
        • et al.
        Polymyositis associated with simvastatin.
        Lancet. 1997; 349: 1600-1601
        • Hansen K.E.
        • Hildebrand J.P.
        • Ferguson E.E.
        • et al.
        Outcomes in 45 patients with statin-associated myopathy.
        Arch Intern Med. 2005; 165: 2671-2676
        • Hill M.D.
        • Bilbao J.M.
        Case of the month: February 1999--54 year old man with severe muscle weakness.
        Brain Pathol. 1999; 9: 607-608
        • Mascitelli L.
        • Pezzetta F.
        • Goldstein M.R.
        Detrimental effect of statin therapy in women with fibromyalgia.
        Arch Intern Med. 2008; 168: 1228-1229
        • Goeb V.
        • Guillemant N.
        • Vittecoq O.
        • Le Loet X.
        Cerivastatin-induced polymyalgia rheumatica-like illness.
        Clin Rheumatol. 2004; 23: 179
        • Liebhaber M.I.
        • Wright R.S.
        • Gelberg H.J.
        • et al.
        Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases.
        Chest. 1999; 115: 886-889
        • Sauret J.M.
        • Marinides G.
        Rhabdomyolysis.
        Am Fam Physician. 2002; 65: 907-912
        • Baker S.K.
        Molecular clues into the pathogenesis of statin-mediated muscle toxicity.
        Muscle Nerve. 2005; 31: 572-580
        • Link E.
        • Parish S.
        • Armitage J.
        • et al.
        SLCO1B1 variants and statin-induced myopathy--a genomewide study.
        N Engl J Med. 2008; 359: 789-799
        • Tirona R.G.
        • Leake B.F.
        • Merino G.
        • et al.
        Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans.
        J Biol Chem. 2001; 276: 35669-35675
        • Vladutiu G.D.
        • Simmons Z.
        • Isackson P.J.
        • et al.
        Genetic risk factors associated with lipid-lowering drug-induced myopathies.
        Muscle Nerve. 2006; 34: 153-162
        • Jacobson T.A.
        Myopathy with statin-fibrate combination therapy: clinical considerations.
        Nat Rev Endocrinol. 2009; 5: 507-518
        • Knauer M.J.
        • Urquhart B.L.
        • Meyer zu Schwabedissen H.E.
        • et al.
        Human skeletal muscle drug transporters determine local exposure and toxicity of statins.
        Circ Res. 2010; 106: 297-306
        • Berthold H.K.
        • Naini A.
        • Di Mauro S.
        • et al.
        Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma : a randomised trial.
        Drug Saf. 2006; 29: 703-712
        • Chariot P.
        • Abadia R.
        • Agnus D.
        • et al.
        Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome.
        Am J Med. 1993; 94: 109-110
        • Colquhoun D.M.
        • Jackson R.
        • Walters M.
        • et al.
        Effects of simvastatin on blood lipids, vitamin E, coenzyme Q10 levels and left ventricular function in humans.
        Eur J Clin Invest. 2005; 35: 251-258
        • De Pinieux G.
        • Chariot P.
        • Ammi-Said M.
        • et al.
        Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio.
        Br J Clin Pharmacol. 1996; 42: 333-337
        • Elmberger P.G.
        • Kalen A.
        • Lund E.
        • et al.
        Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia.
        J Lipid Res. 1991; 32: 935-940
        • Folkers K.
        • Langsjoen P.
        • Willis R.
        • et al.
        Lovastatin decreases coenzyme Q levels in humans.
        Proc Natl Acad Sci U S A. 1990; 87: 8931-8934
        • Ghirlanda G.
        • Oradei A.
        • Manto A.
        • et al.
        Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study.
        J Clin Pharmacol. 1993; 33: 226-229
        • Laaksonen R.
        • Jokelainen K.
        • Sahi T.
        • Tikkanen M.J.
        • Himberg J.J.
        Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans.
        Clin Pharmacol Ther. 1995; 57: 62-66
        • Laaksonen R.
        • Jokelainen K.
        • Laakso J.
        • et al.
        The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle.
        Am J Cardiol. 1996; 77: 851-854
        • Lamperti C.
        • Naini A.B.
        • Lucchini V.
        • et al.
        Muscle coenzyme Q10 level in statin-related myopathy.
        Arch Neurol. 2005; 62: 1709-1712
        • Mabuchi H.
        • Haba T.
        • Tatami R.
        • et al.
        Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia.
        Atheroscler Suppl. 2004; 5: 51-55
        • Mabuchi H.
        • Higashikata T.
        • Kawashiri M.
        • et al.
        Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients.
        J Atheroscler Thromb. 2005; 12: 111-119
        • Rundek T.
        • Naini A.
        • Sacco R.
        • Coates K.
        • DiMauro S.
        Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke.
        Arch Neurol. 2004; 61: 889-892
        • Schaefer W.H.
        • Lawrence J.W.
        • Loughlin A.F.
        • et al.
        Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats.
        Toxicol Appl Pharmacol. 2004; 194: 10-23
        • Stocker R.
        • Pollicino C.
        • Gay C.A.
        • et al.
        Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: a prospective case-control study from the LIPID study.
        Atherosclerosis. 2006; 187: 198-204
        • Strey C.H.
        • Young J.M.
        • Molyneux S.L.
        • et al.
        Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure.
        Atherosclerosis. 2005; 179: 201-206
        • Walravens P.A.
        • Greene C.
        • Frerman F.E.
        Lovastatin, isoprenes, and myopathy.
        Lancet. 1989; 2: 1097-1098
        • Willis R.A.
        • Folkers K.
        • Tucker J.L.
        • et al.
        Lovastatin decreases coenzyme Q levels in rats.
        Proc Natl Acad Sci U S A. 1990; 87: 8928-8930
        • Päivä H.
        • Thelen K.M.
        • Van Coster R.
        • et al.
        High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
        Clin Pharmacol Ther. 2005; 78: 60-68
        • Thomas J.E.
        • Lee N.
        • Thompson P.D.
        Statins Provoking MELAS Syndrome.
        Eur Neurol. 2007; 57: 232-235
        • Oh J.
        • Ban M.R.
        • Miskie B.A.
        • et al.
        Genetic determinants of statin intolerance.
        Lipids Health Dis. 2007; 6: 7
        • Puccetti L.
        • Ciani F.
        • Auteri A.
        Genetic involvement in statins induced myopathy.
        Atherosclerosis. 2010; 211: 28-29
        • Wagner B.K.
        • Kitami T.
        • Gilbert T.J.
        • et al.
        Large-scale chemical dissection of mitochondrial function.
        Nat Biotechnol. 2008; 26: 343-351
        • Baker S.K.
        • Vladutiu G.D.
        • Peltier W.L.
        • Isackson P.J.
        • Tarnopolsky M.A.
        Metabolic myopathies discovered during investigations of statin myopathy.
        Can J Neurol Sci. 2008; 35: 94-97
        • Kaufmann P.
        • Torok M.
        • Zahno A.
        • et al.
        Toxicity of statins on rat skeletal muscle mitochondria.
        Cell Mol Life Sci. 2006; 63: 2415-2425
        • Sirvent P.
        • Mercier J.
        • Vassort G.
        • et al.
        Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle.
        Biochem Biophys Res Commun. 2005; 329: 1067-1075
        • Sacher J.
        • Weigl L.
        • Werner M.
        • et al.
        Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells.
        J Pharmacol Exp Ther. 2005; 314: 1032-1041
        • Tsao C.Y.
        • Mendell J.R.
        Combined partial deficiencies of carnitine palmitoyltransferase II and mitochondrial complex I presenting as increased serum creatine kinase level.
        J Child Neurol. 2002; 17: 304-306
        • Baker S.K.
        • Tarnopolsky M.A.
        Statin myopathies: pathophysiologic and clinical perspectives.
        Clin Invest Med. 2001; 24: 258-272
        • Baker S.K.
        • Samjoo I.A.
        A neuromuscular approach to statin-related myotoxicity.
        Can J Neurol Sci. 2008; 35: 8-21
        • Folzenlogen D.
        A case of atorvastatin combined toxic myopathy and inflammatory myositis.
        J Clin Rheumatol. 2001; 7: 340-345
        • Goldman J.A.
        • Fishman A.B.
        • Lee J.E.
        • Johnson R.J.
        The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis.
        Arthritis Rheum. 1989; 32: 358-359
        • Khattak F.H.
        • Morris I.M.
        • Branford W.A.
        Simvastatin-associated dermatomyositis.
        Br J Rheumatol. 1994; 33: 199
        • Noel B.
        • Cerottini J.P.
        • Panizzon R.G.
        Atorvastatin-induced dermatomyositis.
        Am J Med. 2001; 110: 670-671
        • Schalke B.B.
        • Schmidt B.
        • Toyka K.
        • Hartung H.P.
        Pravastatin-associated inflammatory myopathy.
        N Engl J Med. 1992; 327: 649-650
        • Vasconcelos O.M.
        • Campbell W.W.
        Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake.
        Muscle Nerve. 2004; 30: 803-807
        • Needham M.
        • Fabian V.
        • Knezevic W.
        • et al.
        Progressive myopathy with up-regulation of MHC-I associated with statin therapy.
        Neuromuscul Disord. 2007; 17: 194-200
        • Singh P.
        • Kohr D.
        • Kaps M.
        • Blaes F.
        Skeletal muscle cell MHC I expression: implications for statin-induced myopathy.
        Muscle Nerve. 2010; 41: 179-184
        • Grable-Esposito P.
        • Katzberg H.D.
        • Greenberg S.A.
        • et al.
        Immune-mediated necrotizing myopathy associated with statins.
        Muscle Nerve. 2010; 41: 185-190
        • Christopher-Stine L.
        • Casciola-Rosen L.A.
        • Hong G.
        • et al.
        A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy.
        Arthritis Rheum. 2010; 62: 2757-2766
        • Mammen A.L.
        • Chung T.
        • Christopher-Stine L.
        • et al.
        Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy.
        Arthritis Rheum. 2011; 63: 713-721
        • Laaksonen R.
        • Katajamaa M.
        • Paiva H.
        • et al.
        A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle.
        PLoS One. 2006; 1: e97
        • Bays H.
        Statin safety: an overview and assessment of the data--2005.
        Am J Cardiol. 2006; 97: 6C-26C
        • Harper C.R.
        • Jacobson T.A.
        The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis.
        Curr Opin Lipidol. 2007; 18: 401-408
        • Kashani A.
        • Phillips C.O.
        • Foody J.M.
        • et al.
        Risks associated with statin therapy: a systematic overview of randomized clinical trials.
        Circulation. 2006; 114: 2788-2797
        • Thompson P.D.
        • Clarkson P.
        • Karas R.H.
        Statin-associated myopathy.
        JAMA. 2003; 289: 1681-1690
        • Wilke R.A.
        • Lin D.W.
        • Roden D.M.
        • et al.
        Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.
        Nat Rev. 2007; 6: 904-916
        • Baigent C.
        • Blackwell L.
        • et al.
        • Cholesterol Treatment Trialists' (CTT) Collaboration
        Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
        Lancet. 2010; 376: 1670-1681
        • Chan J.
        • Hui R.L.
        • Levin E.
        Differential association between statin exposure and elevated levels of creatine kinase.
        Ann Pharmacother. 2005; 39: 1611-1616
        • Graham D.J.
        • Staffa J.A.
        • Andrade S.E.
        • et al.
        Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
        JAMA. 2004; 292: 2585-2590
        • Bruckert E.
        • Hayem G.
        • Dejager S.
        • et al.
        Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.
        Cardiovasc Drugs Ther. 2005; 19: 403-414
        • Staffa J.A.
        • Chang J.
        • Green L.
        Cerivastatin and reports of fatal rhabdomyolysis.
        N Engl J Med. 2002; 346: 539-540
        • Silva M.A.
        • Swanson A.C.
        • Gandhi P.J.
        • et al.
        Statin-related adverse events: a meta-analysis.
        Clin Ther. 2006; 28: 26-35
        • Shek A.
        • Ferrill M.J.
        Statin-fibrate combination therapy.
        Ann Pharmacother. 2001; 35: 908-917
        • Evans M.A.
        • Golomb B.A.
        Statin-associated adverse cognitive effects: survey results from 171 patients.
        Pharmacother. 2009; 29: 800-811
        • McGuinness B.
        • Craig D.
        • Bullock R.
        • et al.
        Statins for the prevention of dementia.
        Cochrane Database Syst Rev. 2009; 2 (CD003160)
        • Benito-Léon J.
        • Louis E.D.
        • Vega S.
        • et al.
        Statins and cognitive functioning in the elderly: a population-based study.
        J Alzheimer Dis. 2010; 21: 95-102
        • Muldoon M.F.
        • Manuck S.B.
        • Matthews K.A.
        Lowering cholesterol concentrations and mortality.
        BMJ. 1990; 301: 309-314
        • Davey Smith G.
        • Song F.
        • Sheldon T.A.
        Cholesterol lowering and mortality: the importance of considering initial level of risk.
        BMJ. 1993; 306: 1367-1373
        • Morgan R.
        • Palinkas L.
        • Barrett-Connor E.
        • et al.
        Plasma cholesterol and depressive symptoms in older men.
        Lancet. 1993; 341: 75-79
        • While A.
        • Keen L.
        The effects of statins on mood: a review of the literature.
        Eur J Cardiovasc Nurs. 2010 ([Epub ahead of print])
        • Tuccori M.
        • Lapi F.
        • Testi A.
        • et al.
        Statin-associated psychiatric adverse events.
        Drug Saf. 2008; 31: 1115-1123
        • Schaefer E.J.
        Letter to the editor.
        N Engl J Med. 1988; 319: 1222
        • Black D.M.
        • Lamkin G.
        • Olivera E.H.
        • et al.
        Sleep disturbance and HMG CoA reductase inhibitors.
        JAMA. 1990; 264: 1105
        • Vgontzas A.N.
        • Kales A.
        • Bixler E.O.
        • et al.
        Effects of lovastatin and pravastatin on sleep efficency and sleep stages.
        Clin Pharmacol Ther. 1991; 50: 730-737
        • Ehrenberg B.L.
        • Lamon-Fava S.
        • Corbett K.E.
        • et al.
        Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholersterolemic subjects.
        Sleep. 1999; 22: 117-121
        • Rzouq F.S.
        • Volk M.L.
        • Hatoum H.H.
        • et al.
        Hepatotoxicity fears contribute to underutilization of station medications by primary care physicians.
        Am J Med Sci. 2010; 340: 89-93
        • Calderon R.M.
        • Cubeddu L.X.
        • Golberg R.B.
        • et al.
        Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma.
        Mayo Clin Proc. 2010; 85: 349-356
        • Bhardwaj S.S.
        Lipid lowering agents that cause drug-induced hepatotoxicity.
        Clin Liver Dis. 2007; 11 (vii): 597-613
        • LaRosa J.C.
        • Grundy S.M.
        • Waters D.D.
        • et al.
        Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
        N Engl J Med. 2005; 352: 1425-1435
        • Pfeffer M.A.
        • Keech A.
        • Sacks F.M.
        • et al.
        Safety and tolerability of pravastatin in long-term clinical trials.
        Circulation. 2002; 105: 2341-2346
        • Alla V.
        • Abraham J.
        • Siddiqui J.
        • et al.
        Autoimmune hepatitis triggered by statins.
        J Clin Gastroenterol. 2006; 40: 757-761
        • Gomez-Dominguez E.
        • Gisbert J.P.
        • Moreno-Monteagudo J.A.
        • et al.
        A pilot study of atorvastatin treatment in dyslipemic, non-alcoholic fatty liver patients.
        Aliment Pharmacol Ther. 2006; 23: 1643-1647
        • American Gastroenterological Association
        American Gastroenterological Association medical position statement.
        Gastroenterology. 2002; 123: 1702-1704
        • Wiesinger H.A.
        • Shah J.
        • White A.
        • et al.
        Liver biochemistry abnormalities in a quaternary care lipid clinic database.
        Ann Hepatol. 2008; 7: 63-66
        • Browning J.D.
        Statins and hepatic steatosis: perspectives from the Dallas Heart Study.
        Hepatology. 2006; 44: 466-471
        • Hyogo H.
        • Tazuma S.
        • Arihiro K.
        • et al.
        Efficacy of atorvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia.
        Metab Clin Exp. 2008; 57: 1711-1718
        • Argo C.K.
        • Loria P.
        • Caldwell S.H.
        • et al.
        Statins in liver disease: a molehill, an iceberg or neither?.
        Hepatology. 2008; 48: 662-669
        • Foster T.
        • Budoff M.J.
        • Saab S.
        • et al.
        Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.
        Am J Gastroenterol. 2011; 106: 71-77
        • Tandra S.
        • Vuppalanchi R.
        Use of statins in patients with liver disease.
        Curr Treat Options Cardiovasc Med. 2009; 11: 272-278
        • Aburajab M.A.
        • Kaplan M.M.
        Statin use in patients with primary billiary cirrhosis (PBC): are they safe? [abstract].
        Gastroenterology. 2007; 132: A732
        • Vuppalanchi R.
        • Chalasani N.
        Statins for hyperlipidemia in patients with chronic liver disease: are they safe?.
        Clin Gastroenterol Hepatol. 2006; 4: 838-839
        • Bader T.
        The myth of statin-induced hepatotoxicity.
        Am J Gastroenterol. 2010; 105: 978-980
        • Brown W.V.
        Safety of statins.
        Curr Opin Lipidol. 2008; 19: 558-562
        • Sidaway J.E.
        • Davidson R.G.
        • McTaggart F.
        • et al.
        Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells.
        J Am Soc Nephrol. 2004; 15: 2258-2265
        • Agarwal R.
        Statin induced proteinuria: renal injury or renoprotection?.
        J Am Soc Nephrol. 2004; 15: 2502-2503
        • Verhulst A.
        • D'Haese P.C.
        • De Broe M.E.
        Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells.
        J Am Soc Nephrol. 2004; 15: 2249-2257
        • Fellström B.
        • Holdaas H.
        • Jardine A.G.
        • et al.
        Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial.
        Kidney Int. 2004; 66: 1549-1555
        • Sharp Collaborative Group
        Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
        Am Heart J. 2010; 160: 785-794
        • Wanner C.
        • Krane V.
        • März W.
        • et al.
        Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
        N Engl J Med. 2005; 353: 238-248
        • Fellstrom B.C.
        • Jardine A.G.
        • Schmieder R.E.
        • et al.
        Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
        N Engl J Med. 2009; 360: 1395-1407
        • Fried L.F.
        • Orchard T.J.
        • Kasiske B.L.
        Effect of lipid reduction on the progression of renal disease: a meta-analysis.
        Kidney Int. 2001; 59: 260-269
      1. de Zeeuw D. Different renal protective effects of atorvastatin and rosuvastatin in diabetic and non-diabetic renal patients with proteinuria. Results of the PLANET trials. Presented at: 2010 European Renal Association-European Dialysis and Transplant Association Congress; June 25-28, 2010; Munich, Germany.

        • Kasiske B.L.
        • Wanner C.
        • O'Neill W.C.
        • et al.
        An assessment of statin safety by nephrologists.
        Am J Cardiol. 2006; 97: 82C-85C
        • Freeman D.J.
        • Norrie J.
        • Sattar N.
        • et al.
        Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.
        Circulation. 2001; 103: 357-362
        • Coleman C.I.
        • Reinhart K.
        • Kluger J.
        • et al.
        The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials.
        Curr Med Res Opin. 2008; 24: 1359-1362
        • Rajpathak S.N.
        • Kumbhani D.J.
        • Crandall J.
        • et al.
        Statin therapy and risk of developing type 2 diabetes: a meta-analysis.
        Diabetes Care. 2009; 32: 1924-1929
        • Baker W.L.
        • Talati R.
        • White C.M.
        • et al.
        Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis.
        Diabetes Res Clin Pract. 2010; 87: 98-107
        • Genest J.
        • McPherson R.
        • Frohlich J.
        • et al.
        2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations.
        Can J Cardiol. 2009; 25: 567-579
        • Campian J.
        • Western A.
        Statins and joint pain.
        Br J Clin Phamacol. 2008; 66: 570-571
        • Liebhaber M.I.
        • Wright R.S.
        • Gelberg H.J.
        • Dyer Z.
        • Kupperman J.L.
        Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases.
        Chest. 1999; 115: 886-889
        • Chazerain P.
        • Hayem G.
        • Hamza S.
        • Best C.
        • Ziza J.M.
        Four cases of tendinopathy in patients on statin therapy.
        Jt Bone Spine. 2001; 68: 430-433
        • Movahed M.R.
        • Samsamsharaiat S.A.
        Reproducible tendinitis-like symptoms related to statin therapy.
        J Clin Rheumatol. 2006; 12: 320-321
        • Pullatt R.C.
        • Gadarla M.R.
        • Karas R.H.
        • Alsheikh-Ali A.A.
        • Thompson P.D.
        Tendon rupture associated with simvastatin/ezetimibe therapy.
        Am J Cardiol. 2007; 100: 152-153
        • Marie I.
        • Delafenetre H.
        • Massy N.
        • et al.
        Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature.
        Arthritis Rheum. 2008; 59: 367-372
        • Turner N.A.
        • O'Regan D.J.
        • Ball S.G.
        • Porter K.E.
        Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels.
        FASEB J. 2005; 19: 804-806
        • Beri A.
        • Dwamena F.C.
        • Dwamena B.A.
        Association between statin therapy and tendon rupture.
        J Cardiovasc Pharmacol. 2009; 53: 401-404
        • Beattie M.
        • Lane N.
        • Hung Y.Y.
        • Nevitt M.C.
        Association of statin use and development and progression of hip osteoarthritis in elderly women.
        J Rheumatol. 2005; 32: 106-110
        • Soubrier M.
        • Roux C.
        Statins in rheumatology.
        Joint Bone Spine. 2006; 73: 159-168
        • Roman M.J.
        • Salmon J.E.
        Cardiovascular manifestations of rheumatologic diseases.
        Circulation. 2007; 116: 2346-2355
        • Solomon D.H.
        • Goodson N.J.
        • Katz J.N.
        • et al.
        Patterns of cardiovascular risk in rheumatoid arthritis.
        Ann Rheum Dis. 2006; 65: 1608-1612
        • Kitsas G.D.
        • Gabriel S.
        Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives.
        Ann Rheum Dis. 2011; 70: 8-14
        • Arnaud C.
        • Mach F.
        Potnetial anti-inflammatory and immunomodulator effects of statins in rheumatologic therapy.
        Arthritis Rheum. 2006; 54: 390-392
        • Nurmohamed M.T.
        • Dijkmans B.A.
        Dyslipidaemia, statins and rheumatoid arthritis.
        Ann Rheum Dis. 2009; 68: 453-455
        • McCarey D.W.
        • McInnes E.B.
        • Madhok R.
        • et al.
        Trial of atorvastatin in rheumatoid arthritis (TARA): a double-blind randomised placebo-controlled trial.
        Lancet. 2004; 363: 2015-2021
        • Lodi S.
        • Evans S.J.W.
        • Egger P.
        • Carpenter J.
        Is there an anti-inflammatory effect of statins in rheumatoid arthritis?.
        Br J Clin Pharmacol. 2010; 69: 85-94
        • Toms T.E.
        • Panoulas V.F.
        • Douglas K.M.J.
        • et al.
        Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?.
        Ann Rheum Dis. 2010; 69: 683-688
        • Semb A.G.
        • Holme I.
        • Kvien T.K.
        • Pedersen T.R.
        Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial.
        Rheumatology (Oxford). 2011; 50: 324-329
        • Peters M.J.
        • Symmons D.P.
        • McCarey D.
        • et al.
        EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.
        Ann Rheum Dis. 2010; 69: 325-331
        • Randall V.A.
        Androgens: the main regulator of human hair growth.
        in: Camacho F.M. Randall V.A. Price V.H. Hair and Its Disorders: Biology, Pathology and Management. Martin Dunitz, London2000: 69-82
        • Pfizer Canada Inc
        Lipitor Product Monograph.
        Updated November 17. 2010;
        • Astra Zeneca Canada Inc.
        Crestor Product Monograph.
        Updated October 15. 2010;
        • Merck Frosst Canada Ltd.
        Zocor Product Monograph.
        Updated October 12. 2010;
        • Novartis Pharmaceuticals Canada Inc.
        Lescol Product Monograph.
        Updated October 12. 2010;
        • Bristol-Myers Squibb Canada Inc
        Pravachol Product Monograph.
        Updated October 12. 2010;
        • Merck Frosst Canada Ltd
        Mevacor Product Monograph.
        Updated October 12. 2010;
        • Segal A.S.
        Alopecia associated with atorvastatin.
        Am J Medicine. 2002; 113: 171
        • Robb-Nicholson C.
        Recently, I heard on a TV show that anticholesterol drugs can cause hair loss.
        Harv Womens Health Watch. 1998; 5: 8
        • Lee T.H.
        By the way, doctor … My hair has been thinning out for the past decade or so, but since my doctor started me on Lipitor (atorvastatin) a few months ago for high cholesterol, I swear it's been falling out much faster.
        Harv Health Lett. 2000; 25: 8
        • Nehra A.
        Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.
        Mayo Clin Proc. 2009; 84: 139-148
        • Jones T.H.
        Testosterone associations with erectile dysfunction, diabetes, and the metabolic syndrome.
        Eur Urol Suppl. 2007; 6: 847-857
        • Ferrer E.
        • Moral M.A.
        • Bozzo J.
        The role of statins in erectile dysfunction.
        Drugs Today (Barc). 2007; 43: 55-59
        • Solomon H.
        • Wierzbicki A.S.
        • Lumb P.J.
        • et al.
        Cardiovascular risk factors determine erectile and arterial function response to sildenafil.
        Am J Hypertens. 2006; 19: 915-919
        • Hermann H.C.
        • Levine L.A.
        • Macalusa J.
        • et al.
        Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil?.
        J Sex Med. 2006; 3: 303-308
        • Azzarito C.
        • Boiardi L.
        • Zini M.
        • et al.
        Long-term therapy with high-dose simvastatin does not affect adrenocortical and gonadal hormones in hypercholesterolemic patients.
        Metabolism. 1992; 41: 148-153
        • Dobs A.S.
        • Schrott H.
        • Davidson M.H.
        • et al.
        Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia.
        Metabolism. 2000; 49: 1234-1238
        • Travia D.
        • Tosi F.
        • Negri C.
        • et al.
        Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads.
        J Clin Endocrinol Metab. 1995; 80: 836-840
        • Stanworth R.D.
        • Kapoor D.
        • Channer K.S.
        • et al.
        Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes.
        Diabetes Care. 2009; 32: 541-546
        • Rossato M.
        • Guarneri G.
        • Lavagnini T.
        • et al.
        Simvastatin influences testicular steroidogenesis in human.
        Horm Metab Res. 1993; 25: 503-505
        • Jay R.H.
        • Sturley R.H.
        • Stirling C.
        • et al.
        Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia.
        Br J Clin Pharmacol. 1991; 32: 417-422
        • Hyyppä M.T.
        • Kronholm E.
        • Virtanen A.
        • et al.
        Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men?.
        Psychoneuroendocrinology. 2003; 28: 181-194
        • Corona G.
        • Boddi V.
        • Balercia G.
        • et al.
        The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction.
        J Sex Med. 2010; 7: 1547-1556
        • Hall S.A.
        • Page S.T.
        • Travison T.G.
        • et al.
        Do statins affect androgen levels in men?.
        Cancer Epidemiol Biomarkers Prev. 2007; 16: 1587-1594
      2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1994; 344: 1383-1389
        • Fernandez A.B.
        • Karas R.H.
        • Alsheikh-Ali A.A.
        • Thompson P.D.
        Statins and interstitial lung disease: a systematic review of the literature and of Food and Drug Administration Adverse Event Reports.
        Chest. 2008; 134: 824-830
        • Nichols G.A.
        • Koro C.E.
        Does statin therapy initiation increase the risk for myopathy?.
        Clin Ther. 2007; 29: 1761-1770
        • Holbrook A.
        • Wright M.
        • Sung M.
        • Ribic C.
        • Baker S.
        Statin-associated rhabdomyolysis: Is there a dose-response relationship?.
        Can J Cardiol. 2011; 27: 146-151
        • Vladutiu G.D.
        Genetic predisposition to statin myopathy.
        Curr Opin Rheumatol. 2008; 20: 648-655
        • Fiegenbaum M.
        • da Silveira F.R.
        • Van der Sand C.R.
        • et al.
        The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment.
        Clin Pharmacol Ther. 2005; 78: 551-558
        • Frudakis T.N.
        • Thomas M.J.
        • Ginjupalli S.N.
        • et al.
        CYP2D6*4 polymorphism is associated with statin-induced muscle effects.
        Pharmacogenet Genomics. 2007; 17: 695-707
        • Hermann M.
        • Bogsrud M.P.
        • Molden E.
        • et al.
        Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy.
        Clin Pharmacol Ther. 2006; 79: 532-539
        • Mulder A.B.
        • van Lijf H.J.
        • Bon M.A.
        • et al.
        Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin.
        Clin Pharmacol Ther. 2001; 70: 546-551
        • Ruano G.
        • Thompson P.D.
        • Windemuth A.
        • et al.
        Physiogenomic association of statin-related myalgia to serotonin receptors.
        Muscle Nerve. 2007; 36: 329-335
        • Vaklavas C.
        • Chatzizisis Y.S.
        • Ziakas A.
        • et al.
        Molecular basis of statin-associated myopathy.
        Atherosclerosis. 2009; 202: 18-28
        • Evans M.
        • Rees A.
        Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?.
        Drug Saf. 2002; 25: 649-663
        • Neuvonen P.J.
        • Niemi M.
        • Backman J.T.
        Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance.
        Clin Pharmacol Ther. 2006; 80: 565-581
        • Rosenson R.
        Current overview of statin-induced myopathy.
        Am J Med. 2004; 116: 408-416
        • McClure D.L.
        • Valuck R.J.
        • Glanz M.
        • Murphy J.R.
        • Hokanson J.E.
        Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population.
        J Clin Epidemiol. 2007; 60: 812-818
        • Stefanick M.L.
        • Mackey S.
        • Sheehan M.
        • et al.
        Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol.
        N Engl J Med. 1998; 339: 12-20
        • Schaefer E.J.
        • Lamon-Fava S.
        • Ausman L.M.
        • et al.
        Individual variability in lipoprotein cholesterol response to National Cholesterol Education Program Step 2 diets.
        Am J Clin Nutr. 1997; 65: 823-830
        • Mensink R.P.
        • Katan M.B.
        Effect of a diet enriched with monounsaturated or polyunsaturated fatty acids on levels of low-density and high-density lipoprotein cholesterol in healthy women and men.
        N Engl J Med. 1989; 321: 436-441
        • Kris-Etherton P.M.
        • Pearson T.A.
        • Wan Y.
        • et al.
        High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations.
        Am J Clin Nutr. 1999; 70: 1009-1015
        • Abumweis S.S.
        • Barake R.
        • Jones P.J.
        Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials.
        Food Nutr Res. 2008; 52
        • Jenkins D.J.
        • Leeds A.R.
        • Gassull M.A.
        • et al.
        Decrease in postprandial insulin and glucose concentrations by guar and pectin.
        Ann Intern Med. 1977; 86: 20-23
        • Bourdon I.
        • Yokoyama W.
        • Davis P.
        • et al.
        Postprandial lipid, glucose, insulin and cholecystokinin responses in men fed barley pasta enriched with beta-glucan.
        Am J Clin Nutr. 1999; 69: 55-63
        • Kendall C.W.
        • Jenkins D.J.
        A dietary portfolio: maximal reduction of low-density lipoprotein cholesterol with diet.
        Curr Atheroscler Rep. 2004; 6: 492-498
        • Jenkins D.J.
        • Kendall C.W.
        • Marchie A.
        • et al.
        Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein.
        JAMA. 2003; 290: 502-510
        • Dattilo A.M.
        • Kris-Etherton P.M.
        Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis.
        Am J Clin Nutr. 1992; 56: 320-328
        • Halbert S.C.
        • French B.
        • Gordon R.Y.
        • et al.
        Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.
        Am J Cardiol. 2010; 105: 198-204
        • Becker D.J.
        • Gordon R.Y.
        • Halbert S.C.
        • et al.
        Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial.
        Ann Intern Med. 2009; 150: 830-839
        • Gordon R.Y.
        • Becker D.J.
        The role of red yeast rice for the physician.
        Curr Atheroscler Rep. 2011; 13: 73-80
        • Stein E.A.
        • Ballantyne C.M.
        • Windler E.
        • et al.
        Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
        Am J Cardiol. 2008; 101: 490-496
        • Degreef L.E.
        • Opdam F.L.
        • Teepe-Twiss I.M.
        • et al.
        The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients.
        Eur J Intern Med. 2010; 21: 293-296
        • Glueck C.J.
        • Aregawi D.
        • Agloria M.
        • et al.
        Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
        Clin Ther. 2006; 28: 933-942
        • Backes J.M.
        • Venero C.V.
        • Gibson C.A.
        • et al.
        Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance.
        Ann Pharmacother. 2008; 42: 341-346
        • Joy T.
        • Hegele R.A.
        Alternate day dosing of rosuvastatin: potential usefulness in statin-intolerant patients [comment on Can J Cardiol 2009;25:e28-31].
        Can J Cardiol. 2009; 25: 453
        • Backes J.M.
        • Moriarty P.M.
        • Ruisinger J.F.
        • et al.
        Effects of once weekly rosuvastatin among patients with a prior statin intolerance.
        Am J Cardiol. 2007; 100: 554-555
        • Jia L.
        • Betters J.L.
        • Yu L.
        Niemann-Pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.
        Annu Rev Physiol. 2011; 73: 239-259
        • Hegele R.A.
        • Guy J.
        • Ban M.R.
        • et al.
        NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe.
        Lipids Health Dis. 2005; 4: 16
        • Athyros V.G.
        • Tziomalos K.
        • Kakafika A.I.
        • et al.
        Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.
        Am J Cardiol. 2008; 101: 483-485
        • Stein E.A.
        • Ballantyne C.M.
        • Windler E.
        • et al.
        Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
        Am J Cardiol. 2008; 101: 490-496
        • Zema M.J.
        Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia.
        Am J Ther. 2005; 12: 306-310
        • Brooks E.L.
        • Kuvin J.T.
        • Karas R.H.
        Niacin's role in the statin era.
        Expert Opin Pharmacother. 2010; 11: 2291-2300
        • Bays H.E.
        • Shah A.
        • Lin J.
        • et al.
        Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
        J Clin Lipidol. 2010; 4: 515-521
        • Berge K.G.
        • Canner P.L.
        Coronary drug project: experience with niacin.
        Eur J Clin Pharmacol. 1991; 40: S49-S51
        • Goldenberg I.
        • Benderly M.
        • Goldbourt U.
        Update on the use of fibrates: focus on bezafibrate.
        Vasc Health Risk Manag. 2008; 4: 131-141
        • Tenenbaum H.
        • Behar S.
        • Boyko V.
        • et al.
        Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes.
        Atherosclerosis. 2007; 194: 265-271
        • Tenenbaum A.
        • Motro M.
        • Fisman E.Z.
        • et al.
        Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.
        Eur Heart J. 2005; 26: 2032-2038
        • Asztalos B.F.
        • Collins D.
        • Cupples L.A.
        • et al.
        Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial.
        Arterioscler Thromb Vasc Biol. 2005; 25: 2185-2191
        • Scott R.
        • O'Brien R.
        • Fulcher G.
        • et al.
        Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
        Diabetes Care. 2009; 32: 493-498
        • The BIP Study Group
        Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study.
        Circulation. 2000; 102: 21-27
        • Tenenbaum A.
        • Motro M.
        • Fisman E.Z.
        • et al.
        Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.
        Arch Intern Med. 2005; 165: 1154-1160
        • Goldenberg I.
        • Benderly M.
        • Goldbourt U.
        • et al.
        Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial.
        J Am Coll Cardiol. 2008; 51: 459-465
        • Jun M.
        • Foote C.
        • Lv J.
        • et al.
        Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.
        Lancet. 2010; 375: 1875-1884
        • ACCORD Study Group
        Effects of combination lipid therapy in type 2 diabetes mellitus.
        N Engl J Med. 2010; 362: 1563-1574
        • Bays H.E.
        • Goldberg R.B.
        The ‘forgotten’ bile acid sequestrants: is now a good time to remember?.
        Am J Ther. 2007; 14: 567-580
        • Jacobson T.A.
        • Armani A.
        • McKenney J.M.
        • Guyton J.R.
        Safety considerations with gastrointestinally active lipid-lowering drugs.
        Am J Cardiol. 2007; 99: 47C-55C
        • Thompson G.R.
        • HEART-UK LDL Apheresis Working Group
        Recommendations for the use of LDL apheresis.
        Atherosclerosis. 2008; 198: 247-255
        • Thompson G.R.
        • Barbir M.
        • Davies D.
        • et al.
        Efficacy criteria and cholesterol targets for LDL apheresis.
        Atherosclerosis. 2010; 208: 317-321
        • Richter W.O.
        • Donner M.G.
        • Schwandt P.
        Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation.
        Ther Apher. 1999; 3: 203-208
        • Gordon B.R.
        Incorporation of low-density lipoprotein apheresis into the treatment program of patients with severe hypercholesterolemia.
        Curr Atheroscler Rep. 2000; 2: 308-313
        • Matsuzaki M.
        • Hiramori K.
        • Imaizumi T.
        • et al.
        Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the low density lipoprotein-apheresis coronary morphology and reserve trial (LACMART).
        J Am Coll Cardiol. 2002; 40: 220-227
        • Coker M.
        • Ucar S.K.
        • Simsek D.G.
        • et al.
        Low density lipoprotein apheresis in pediatric patients with homozygous familial hypercholesterolemia.
        Ther Apher Dial. 2009; 13: 121-128
        • Akdim F.
        • Visser M.E.
        • Tribble D.L.
        • et al.
        Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
        Am J Cardiol. 2010; 105: 1413-1419
        • Abifadel M.
        • Pakradouni J.
        • Collin M.
        • et al.
        Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.
        Expert Opin Ther Pat. 2010; 20: 1547-1571
        • Visser M.E.
        • Kastelein J.J.
        • Stroes E.S.
        Apolipoprotein B synthesis inhibition: results from clinical trials.
        Curr Opin Lipidol. 2010; 21: 319-323
        • Cannon C.P.
        • Shah S.
        • Dansky H.M.
        • et al.
        Safety of anacetrapib in patients with or at high risk for coronary heart disease.
        N Engl J Med. 2010; 363: 2406-2415
        • Chan J.C.
        • Piper D.E.
        • Cao Q.
        • et al.
        A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.
        Proc Natl Acad Sci U S A. 2009; 106: 9820-9825
        • Cuchel M.
        • Bloedon L.T.
        • Szapary P.O.
        • et al.
        Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia.
        N Engl J Med. 2007; 356: 148-156
        • Caso G.
        • Kelly P.
        • McNurlan M.A.
        • et al.
        Effect of coenzyme q10 on myopathic symptoms in patients treated with statins.
        Am J Cardiol. 2007; 99: 1409-1412
        • Young J.M.
        • Florkowski C.M.
        • Molyneux S.L.
        • et al.
        Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia.
        Am J Cardiol. 2007; 100: 1400-1403
        • Marcoff L.
        • Thompson P.D.
        The role of coenzyme Q10 in statin-associated myopathy: a systematic review.
        J Am Coll Cardiol. 2007; 49: 2231-2237
        • Ahmed W.
        • Khan N.
        • Glueck C.J.
        • et al.
        Low serum 25 (OH) vitamin D levels (< 32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients.
        Transl Res. 2009; 153: 11-16
        • Gupta A.
        • Thompson P.D.
        The relationship of vitamin D deficiency to statin myopathy.
        Atherosclerosis. 2011; 215: 23-29
        • Rosanoff A.
        • Seelig M.S.
        Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals.
        J Am Coll Nutr. 2004; 5: 501S-505S
        • El-Tawil S.
        • Al Musa T.
        • Valli H.
        • et al.
        Quinine for muscle cramps.
        Cochrane Database Syst Rev. 2010; 12 (CD005044)
        • Tajiri K.
        • Shimizu Y.
        Practical guidelines for diagnosis and early management of drug-induced liver injury.
        World J Gastroenterol. 2008; 14: 6774-6785
        • US Food and Drug Administration
        Guidance for industry.
        Drug-induced liver injury: premarketing clinical evaluation. July 2009 (Accessed July 22, 2011)